Guardant Health Inc.
Guardant Health Reports Strong Q2 2024 Results and Raises Revenue Guidance
Summary
Guardant Health, Inc. reported a 29% increase in revenue for the second quarter of 2024, reaching $177.2 million. The company raised its 2024 revenue guidance to a new range of $690 to $700 million, reflecting strong clinical and biopharma volume growth and Guardant360 ASP tailwinds. Guardant360 saw a major upgrade on the Smart Liquid Biopsy platform, and Shield, a blood test for colorectal cancer screening, received FDA approval and is now commercially available. These updates and milestones are detailed in the furnished press release as Exhibit 99.1.
Profitelligence Alerts
Get alerts for GH
Be first to know when Guardant Health Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Guardant Health Inc.
Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.
Official SEC Documents
Advertisement